Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation
Part of paid clinical trials in Ann Arbor, Michigan.
- Sponsor
- University of Michigan Rogel Cancer Center
- Study ID
- NCT05945121
- Status
- Recruiting
Conditions
- Hematopoietic Stem Cell Transplant
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Cardio-oncology program — OTHERConsented patients will undergo an initial CV evaluation as part of standard of care then participate in an 8-week at-home, personalized exercise intervention followed by an additional CV assessment prior to HSCT (after 8-weeks)
Study Details
To assess the feasibility and preliminary effectiveness of a Cardio-Oncology Prehabilitation program in patients at high-risk of developing Cardiovascular (CV) events in improving Cardiorespiratory fitness (CRF) and reducing acute CV complications in Hematopoietic stem cell transplant (HSCT) recipients.
Key Dates
- Start date
- Aug 25, 2023
- Status verified
- May 2026
- Primary completion
- Aug 31, 2027
- Completion
- Aug 31, 2027
Study Design
- Enrollment
- 10 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Experimental: Cardio-oncology programThe cardio-oncology program consists of a multimodal approach, which includes individualized exercise prescription following a detailed CV assessment and medical management of CV risk factors occurring over 8 weeks.
Primary Outcome Measure
Feasibility of a cardio-oncology prehabilitation program in high-risk HSCT candidates (Recruitment Rate). [ Time Frame: 8 weeks post enrollment ]
Central Contacts
- Cancer AnswerLine1-800-865-1125
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Michigan Rogel Cancer Center | Ann Arbor | Michigan | 48109 | Salim Hayek (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Ann Arbor, MI
By research site
Related Studies
- T Cell Therapy of Opportunistic Cytomegalovirus InfectionEARLY_PHASE1 · Recruiting · Mari Dallas · Cleveland, Ohio
- Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell TransplantNot Yet Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Positive Psychology Intervention for Hematopoietic Stem Cell Transplantation SurvivorsRecruiting · Brigham and Women's Hospital · Tampa, Florida
- Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)PHASE1 · Recruiting · Tr1X, Inc. · Duarte, California